Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 2, 2003 - Issue 3
Submit an article Journal homepage
43
Views
9
CrossRef citations to date
0
Altmetric
Review

Hepatotoxic profile of catecholOmethyltranferase inhibitors in Parkinson’s disease

Reina Benabou The Center for Parkinson’s Disease and Other Movement Disorders, New York-Presbyterian Hospital, Columbia Presbyterian Medical Center, The Neurological Institute, 710 West 168th Street, Room 350, New York, NY 10032, USA, [email protected]
&
Cheryl Waters The Neurological Institute, Columbia Presbyterian Medical Center, New York, New York, USA
Pages 263-267 | Published online: 03 Mar 2005

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Thomas Müller. (2020) Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 16:5, pages 403-414.
Read now
Mehboob Ali, Sagheer Ahmed Khan, Peter S. Chang, Rizwanul Haque, Kanchan Bhatia & Saif Ahmad. (2014) Habb-e-Asgand, polyherbal Unani formulation, protects liver and antioxidative enzymes against paracetamol induced hepatotoxicity. Pharmaceutical Biology 52:4, pages 506-515.
Read now
Thomas Müller. (2010) Entacapone. Expert Opinion on Drug Metabolism & Toxicology 6:8, pages 983-993.
Read now
John C L Erve. (2006) Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology. Expert Opinion on Drug Metabolism & Toxicology 2:6, pages 923-946.
Read now
Nuno Borges. (2005) Tolcapone in Parkinson’s disease: liver toxicity and clinical efficacy. Expert Opinion on Drug Safety 4:1, pages 69-73.
Read now

Articles from other publishers (4)

Joseph P. Schacht, Matthew Kubicki & Raymond F. Anton. (2023) A randomized trial of the effects of COMT inhibition on subjective response to alcohol: Moderation by baseline COMT activity and mediation of alcohol self‐administration. Alcohol: Clinical and Experimental Research.
Crossref
Amy Louise Ball, Carol E Jolly, Mark G Lennon, Jonathan J Lyon, Ana Alfirevic & Amy E Chadwick. (2023) The generation of HepG2 transmitochondrial cybrids to reveal the role of mitochondrial genotype in idiosyncratic drug-induced liver injury. eLife 12.
Crossref
Leah M. Norona, Aaron Fullerton, Chris Lawson, Leslie Leung, Jochen Brumm, Tomomi Kiyota, Jonathan Maher, Cyrus Khojasteh & William R. Proctor. (2020) In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk. Archives of Toxicology 94:9, pages 3185-3200.
Crossref
DM Longo, Y Yang, PB Watkins, BA Howell & SQ Siler. (2016) Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym ® , a Mechanistic Model of Drug‐Induced Liver Injury . CPT: Pharmacometrics & Systems Pharmacology 5:1, pages 31-39.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.